학술논문

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial
Document Type
Article
Source
In The Lancet 17 December 2022-6 January 2023 400(10369):2210-2220
Subject
Primary Research
Articles
Language
ISSN
0140-6736